EA201170312A1 - Селективные антитела к гепцидину-25 и их применение - Google Patents
Селективные антитела к гепцидину-25 и их применениеInfo
- Publication number
- EA201170312A1 EA201170312A1 EA201170312A EA201170312A EA201170312A1 EA 201170312 A1 EA201170312 A1 EA 201170312A1 EA 201170312 A EA201170312 A EA 201170312A EA 201170312 A EA201170312 A EA 201170312A EA 201170312 A1 EA201170312 A1 EA 201170312A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- hepcidine
- application
- humans
- selective antibodies
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 238000005534 hematocrit Methods 0.000 abstract 1
- 102000009052 human hepcidin 25 Human genes 0.000 abstract 1
- 108700022871 human hepcidin 25 Proteins 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000001995 reticulocyte Anatomy 0.000 abstract 1
- 238000003118 sandwich ELISA Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8655708P | 2008-08-06 | 2008-08-06 | |
| PCT/US2009/052044 WO2010017070A1 (en) | 2008-08-06 | 2009-07-29 | Anti-hepcidin-25 selective antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170312A1 true EA201170312A1 (ru) | 2012-03-30 |
Family
ID=41165490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170312A EA201170312A1 (ru) | 2008-08-06 | 2009-07-29 | Селективные антитела к гепцидину-25 и их применение |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8609817B2 (enExample) |
| EP (1) | EP2328931B1 (enExample) |
| JP (1) | JP5730200B2 (enExample) |
| KR (1) | KR101462307B1 (enExample) |
| CN (1) | CN102112489B (enExample) |
| AU (1) | AU2009279865B2 (enExample) |
| BR (1) | BRPI0916624A2 (enExample) |
| CA (1) | CA2733497C (enExample) |
| DK (1) | DK2328931T3 (enExample) |
| EA (1) | EA201170312A1 (enExample) |
| ES (1) | ES2432018T3 (enExample) |
| IL (1) | IL210643A (enExample) |
| MX (1) | MX2011001363A (enExample) |
| NZ (1) | NZ590863A (enExample) |
| PL (1) | PL2328931T3 (enExample) |
| PT (1) | PT2328931E (enExample) |
| UA (1) | UA103032C2 (enExample) |
| WO (1) | WO2010017070A1 (enExample) |
| ZA (1) | ZA201100261B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2543630T3 (es) * | 2003-04-01 | 2015-08-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y sus epítopos |
| PE20091261A1 (es) * | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| EP2791684B1 (en) | 2011-12-12 | 2017-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US20140120560A1 (en) * | 2012-10-26 | 2014-05-01 | Claresa Levetan | Generation of new pancreatic beta cells |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| WO2014152006A2 (en) * | 2013-03-15 | 2014-09-25 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
| EP3052522B1 (en) * | 2013-10-03 | 2019-12-11 | Biocare Medical, LLC | Anti-sox10 antibody systems and methods |
| JPWO2016027469A1 (ja) * | 2014-08-21 | 2017-06-01 | 国立大学法人旭川医科大学 | ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法 |
| CA2961917A1 (en) * | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| EP3518971A4 (en) * | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| BR112019013107A2 (pt) | 2016-12-22 | 2019-12-17 | Univ Degli Studi Magna Graecia Catanzaro | anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| CN109948371B (zh) * | 2019-03-07 | 2021-06-25 | 深圳市智税链科技有限公司 | 为区块链节点发放身份证书的方法及相关装置 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| EP4279924A4 (en) * | 2021-01-18 | 2024-06-26 | FUJIFILM Corporation | HEPCIDIN ABSORPTION INHIBITOR, ABSORPTION INHIBITION METHOD, REFERENCE, REAGENT, KIT, AND MEASUREMENT METHOD |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3774300A (en) | 1999-06-02 | 2000-12-18 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| DE60231804D1 (de) * | 2001-05-25 | 2009-05-14 | Inst Nat Sante Rech Med | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| US8017737B2 (en) * | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| WO2004058044A2 (en) | 2002-11-19 | 2004-07-15 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| CA2531482A1 (en) | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| WO2005033327A2 (en) | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
| WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| KR101310000B1 (ko) | 2005-03-11 | 2013-09-25 | 싸이퍼젠 바이오시스템즈, 인코포레이티드 | 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 |
| US8629250B2 (en) | 2007-02-02 | 2014-01-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
| GR1006896B (el) * | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| PE20091261A1 (es) | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
-
2009
- 2009-07-29 UA UAA201101111A patent/UA103032C2/uk unknown
- 2009-07-29 PL PL09790908T patent/PL2328931T3/pl unknown
- 2009-07-29 US US13/055,201 patent/US8609817B2/en not_active Expired - Fee Related
- 2009-07-29 PT PT97909089T patent/PT2328931E/pt unknown
- 2009-07-29 AU AU2009279865A patent/AU2009279865B2/en not_active Ceased
- 2009-07-29 ES ES09790908T patent/ES2432018T3/es active Active
- 2009-07-29 WO PCT/US2009/052044 patent/WO2010017070A1/en not_active Ceased
- 2009-07-29 EP EP09790908.9A patent/EP2328931B1/en active Active
- 2009-07-29 BR BRPI0916624A patent/BRPI0916624A2/pt not_active IP Right Cessation
- 2009-07-29 NZ NZ590863A patent/NZ590863A/xx not_active IP Right Cessation
- 2009-07-29 JP JP2011522119A patent/JP5730200B2/ja not_active Expired - Fee Related
- 2009-07-29 CN CN200980129864.0A patent/CN102112489B/zh not_active Expired - Fee Related
- 2009-07-29 MX MX2011001363A patent/MX2011001363A/es active IP Right Grant
- 2009-07-29 EA EA201170312A patent/EA201170312A1/ru unknown
- 2009-07-29 KR KR1020117002748A patent/KR101462307B1/ko not_active Expired - Fee Related
- 2009-07-29 CA CA2733497A patent/CA2733497C/en active Active
- 2009-07-29 DK DK09790908.9T patent/DK2328931T3/da active
-
2011
- 2011-01-10 ZA ZA2011/00261A patent/ZA201100261B/en unknown
- 2011-01-13 IL IL210643A patent/IL210643A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2733497A1 (en) | 2010-02-11 |
| JP5730200B2 (ja) | 2015-06-03 |
| US20110189190A1 (en) | 2011-08-04 |
| ES2432018T3 (es) | 2013-11-29 |
| CA2733497C (en) | 2015-06-02 |
| DK2328931T3 (da) | 2013-09-30 |
| WO2010017070A1 (en) | 2010-02-11 |
| KR101462307B1 (ko) | 2014-11-17 |
| HK1156326A1 (en) | 2012-06-08 |
| NZ590863A (en) | 2012-10-26 |
| KR20110031963A (ko) | 2011-03-29 |
| PT2328931E (pt) | 2013-11-07 |
| US8609817B2 (en) | 2013-12-17 |
| CN102112489A (zh) | 2011-06-29 |
| EP2328931B1 (en) | 2013-08-14 |
| EP2328931A1 (en) | 2011-06-08 |
| PL2328931T3 (pl) | 2014-01-31 |
| JP2011530514A (ja) | 2011-12-22 |
| UA103032C2 (uk) | 2013-09-10 |
| IL210643A (en) | 2015-09-24 |
| AU2009279865A1 (en) | 2010-02-11 |
| AU2009279865B2 (en) | 2013-10-10 |
| BRPI0916624A2 (pt) | 2015-12-01 |
| MX2011001363A (es) | 2011-04-26 |
| IL210643A0 (en) | 2011-03-31 |
| CN102112489B (zh) | 2014-05-14 |
| ZA201100261B (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170312A1 (ru) | Селективные антитела к гепцидину-25 и их применение | |
| EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
| EA200701211A1 (ru) | Полипептиды, которые связываются с br3, и их применение | |
| EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение | |
| EA201891500A3 (ru) | Белки, связывающиеся с cgrp-рецепторами человека | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| WO2017085172A3 (en) | Improved serum albumin binders | |
| EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
| WO2007067730A3 (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use | |
| EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
| EP3255063A3 (en) | Antibodies to matrix metalloproteinase 9 | |
| MX358705B (es) | Agentes de union de esclerostina. | |
| EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
| PH12014502184A1 (en) | Anti-hla-b* 27 antibodies and uses thereof | |
| MA33757B1 (fr) | Protéines de liaison à l'antigène de l'il-23 humaine | |
| EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
| HK1207655A1 (en) | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use | |
| JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل | |
| EA201170764A1 (ru) | Моноклональные антитела против ферропортина 1 и их применение | |
| Kogan et al. | Immunological study of complex formation between soluble transferrin receptor and transferrin | |
| TW200718711A (en) | Polypeptides that bind BR3 and uses thereof | |
| EA202092850A1 (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH | |
| TH148296B (th) | แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9) | |
| TH136515A (th) | แอนติบอดีของคนที่มีสัมพรรคภาพสูงต่อแองจิโอโพอิทิน-2-ของคน | |
| EA201991246A1 (ru) | Моно- и биспецифические антитела, связывающиеся с фактором коагуляции ix и фактором коагуляции x |